Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Patrick Yung Chih Wen, M.D.

Co-Author

This page shows the publications co-authored by Patrick Wen and Tracy Batchelor.
Connection Strength

7.286
  1. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 2020 08 17; 22(8):1073-1113.
    View in: PubMed
    Score: 0.234
  2. Exploring Predictors of Response to Dacomitinib in EGFR-Amplified Recurrent Glioblastoma. JCO Precis Oncol. 2020; 4.
    View in: PubMed
    Score: 0.231
  3. Biological activity of weekly ONC201 in adult recurrent glioblastoma patients. Neuro Oncol. 2020 01 11; 22(1):94-102.
    View in: PubMed
    Score: 0.225
  4. Letter: When Less is More: Dexamethasone Dosing for Brain Tumors. Neurosurgery. 2019 09 01; 85(3):E607-E608.
    View in: PubMed
    Score: 0.219
  5. Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. J Clin Oncol. 2019 03 20; 37(9):741-750.
    View in: PubMed
    Score: 0.211
  6. Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma. Clin Cancer Res. 2018 10 01; 24(19):4643-4649.
    View in: PubMed
    Score: 0.202
  7. Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate. Nat Commun. 2018 04 16; 9(1):1474.
    View in: PubMed
    Score: 0.199
  8. Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival. NPJ Precis Oncol. 2017; 1.
    View in: PubMed
    Score: 0.188
  9. A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma. Oncotarget. 2017 Oct 03; 8(45):79298-79304.
    View in: PubMed
    Score: 0.187
  10. A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma. Oncotarget. 2017 May 12.
    View in: PubMed
    Score: 0.187
  11. Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-ß tyrosine kinase inhibitor, in patients with recurrent glioblastoma. Neuro Oncol. 2017 04 01; 19(4):567-575.
    View in: PubMed
    Score: 0.185
  12. Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas. J Neurooncol. 2017 03; 132(1):181-188.
    View in: PubMed
    Score: 0.183
  13. A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. Clin Cancer Res. 2015 Aug 15; 21(16):3610-8.
    View in: PubMed
    Score: 0.162
  14. Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. Neuro Oncol. 2015 Jun; 17(6):862-7.
    View in: PubMed
    Score: 0.159
  15. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Neurology. 2015 Jan 20; 84(3):280-6.
    View in: PubMed
    Score: 0.158
  16. Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study. J Neurooncol. 2015 Feb; 121(3):627-34.
    View in: PubMed
    Score: 0.158
  17. Increased perfusion due to vascular normalization improves oxygenation and survival in glioblastoma patients treated with cediranib with or without chemoradiation. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii12.
    View in: PubMed
    Score: 0.153
  18. Phase ii trial of the phosphatidyinositol-3 kinase (pi3k) inhibitor buparlisib (bkm120) in recurrent glioblastoma conducted by the ivy foundation early phase clinical trials consortium. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii47.
    View in: PubMed
    Score: 0.153
  19. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci U S A. 2013 Nov 19; 110(47):19059-64.
    View in: PubMed
    Score: 0.146
  20. Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. Neuro Oncol. 2013 Jul; 15(7):930-5.
    View in: PubMed
    Score: 0.141
  21. Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma. J Neurooncol. 2012 Mar; 107(1):133-8.
    View in: PubMed
    Score: 0.127
  22. It is time to include patients with brain tumors in phase I trials in oncology. J Clin Oncol. 2011 Aug 20; 29(24):3211-3.
    View in: PubMed
    Score: 0.125
  23. Preliminary results from a multicenter, phase II, randomized, noncomparative clinical trial of radiation and temozolomide with or without vandetanib in newly diagnosed glioblastoma (GBM). J Clin Oncol. 2011 May 20; 29(15_suppl):2069.
    View in: PubMed
    Score: 0.123
  24. A phase I trial of LBH589 and bevacizumab for recurrent high-grade glioma (HGG). J Clin Oncol. 2011 May 20; 29(15_suppl):2050.
    View in: PubMed
    Score: 0.123
  25. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. J Clin Oncol. 2011 May 20; 29(15_suppl):2040.
    View in: PubMed
    Score: 0.123
  26. Phase I study of aflibercept (VEGF Trap) and temozolomide in newly diagnosed, high-grade glioma. J Clin Oncol. 2011 May 20; 29(15_suppl):2043.
    View in: PubMed
    Score: 0.123
  27. Phase II study of dose-intense temozolomide in recurrent glioblastoma. J Clin Oncol. 2011 May 20; 29(15_suppl):2038.
    View in: PubMed
    Score: 0.123
  28. Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide. J Neurooncol. 2011 Jun; 103(2):325-32.
    View in: PubMed
    Score: 0.118
  29. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol. 2010 Jun 10; 28(17):2817-23.
    View in: PubMed
    Score: 0.115
  30. Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors. Neuro Oncol. 2010 Jun; 12(6):603-7.
    View in: PubMed
    Score: 0.113
  31. Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys. 2010 Sep 01; 78(1):85-90.
    View in: PubMed
    Score: 0.113
  32. Phase Ib study of cediranib in combination with daily temozolomide and radiation in patients with newly diagnosed glioblastoma. J Clin Oncol. 2009 May 20; 27(15_suppl):e13010.
    View in: PubMed
    Score: 0.107
  33. Phase I trial of vatalanib (PTK787) in combination with standard radiation and temozolomide in patients with newly diagnosed glioblastoma. J Clin Oncol. 2009 May 20; 27(15_suppl):2035.
    View in: PubMed
    Score: 0.107
  34. A phase II study of XL184 in patients (pts) with progressive glioblastoma multiforme (GBM) in first or second relapse. J Clin Oncol. 2009 May 20; 27(15_suppl):2047.
    View in: PubMed
    Score: 0.107
  35. CNS Hodgkin lymphoma. Blood. 2008 Sep 01; 112(5):1658-61.
    View in: PubMed
    Score: 0.101
  36. A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2009 Jan 01; 73(1):222-7.
    View in: PubMed
    Score: 0.100
  37. Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. Neuro Oncol. 2008 Jun; 10(3):300-8.
    View in: PubMed
    Score: 0.099
  38. Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma. J Neurooncol. 2008 Jan; 86(2):211-5.
    View in: PubMed
    Score: 0.096
  39. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro Oncol. 2007 Jul; 9(3):354-63.
    View in: PubMed
    Score: 0.093
  40. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007 Jan; 11(1):83-95.
    View in: PubMed
    Score: 0.091
  41. Phase II study of antiangiogenic (metronomic) chemotherapy for recurrent malignant gliomas. J Clin Oncol. 2006 Jun 20; 24(18_suppl):1569.
    View in: PubMed
    Score: 0.088
  42. Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas. Neuro Oncol. 2006 Jan; 8(1):38-46.
    View in: PubMed
    Score: 0.085
  43. Comparison of 1D, 2D, 3D and volumetric parameters in measuring tumor response in high-grade gliomas in adults. J Clin Oncol. 2004 Jul 15; 22(14_suppl):1523.
    View in: PubMed
    Score: 0.077
  44. Mechanisms and therapeutic implications of hypermutation in gliomas. Nature. 2020 04; 580(7804):517-523.
    View in: PubMed
    Score: 0.057
  45. Automatic assessment of glioma burden: a deep learning algorithm for fully automated volumetric and bidimensional measurement. Neuro Oncol. 2019 11 04; 21(11):1412-1422.
    View in: PubMed
    Score: 0.055
  46. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201. J Neurooncol. 2019 Oct; 145(1):97-105.
    View in: PubMed
    Score: 0.055
  47. Solid stress in brain tumours causes neuronal loss and neurological dysfunction and can be reversed by lithium. Nat Biomed Eng. 2019 03; 3(3):230-245.
    View in: PubMed
    Score: 0.052
  48. Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism. Clin Cancer Res. 2019 04 01; 25(7):2305-2313.
    View in: PubMed
    Score: 0.052
  49. Increase of pseudoprogression and other treatment related effects in low-grade glioma patients treated with proton radiation and temozolomide. J Neurooncol. 2019 Mar; 142(1):69-77.
    View in: PubMed
    Score: 0.052
  50. Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. Neuro Oncol. 2018 08 02; 20(9):1240-1250.
    View in: PubMed
    Score: 0.051
  51. Neurologic emergencies in cancer patients. Neurol Clin. 1998 May; 16(2):449-83.
    View in: PubMed
    Score: 0.050
  52. Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials. Clin Cancer Res. 2017 Oct 01; 23(19):5745-5756.
    View in: PubMed
    Score: 0.047
  53. Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro Oncol. 2017 04 01; 19(4):535-545.
    View in: PubMed
    Score: 0.046
  54. Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma. J Neurooncol. 2017 02; 131(3):603-610.
    View in: PubMed
    Score: 0.045
  55. Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma. Clin Cancer Res. 2016 06 15; 22(12):2885-96.
    View in: PubMed
    Score: 0.043
  56. Repeatability of Cerebral Perfusion Using Dynamic Susceptibility Contrast MRI in Glioblastoma Patients. Transl Oncol. 2015 Jun; 8(3):137-46.
    View in: PubMed
    Score: 0.041
  57. A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma. Neuro Oncol. 2015 Oct; 17(10):1386-92.
    View in: PubMed
    Score: 0.041
  58. Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma. J Neurooncol. 2015 Feb; 121(3):557-63.
    View in: PubMed
    Score: 0.039
  59. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol. 2015 Jan; 17(1):116-21.
    View in: PubMed
    Score: 0.039
  60. Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation. Oncologist. 2014 Jan; 19(1):75-81.
    View in: PubMed
    Score: 0.037
  61. Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy. Nat Med. 2013 Sep; 19(9):1178-83.
    View in: PubMed
    Score: 0.036
  62. Reply to B. Freidlin et al. J Clin Oncol. 2013 Mar 01; 31(7):970-1.
    View in: PubMed
    Score: 0.035
  63. Prospective, high-throughput molecular profiling of human gliomas. J Neurooncol. 2012 Oct; 110(1):89-98.
    View in: PubMed
    Score: 0.033
  64. Bayesian adaptive randomized trial design for patients with recurrent glioblastoma. J Clin Oncol. 2012 Sep 10; 30(26):3258-63.
    View in: PubMed
    Score: 0.033
  65. Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res. 2012 Jan 15; 72(2):402-7.
    View in: PubMed
    Score: 0.032
  66. Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. Cancer Res. 2011 Jan 01; 71(1):19-28.
    View in: PubMed
    Score: 0.030
  67. Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. Neuro Oncol. 2010 May; 12(5):466-72.
    View in: PubMed
    Score: 0.028
  68. A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res. 2009 Jul 01; 69(13):5296-300.
    View in: PubMed
    Score: 0.027
  69. Response criteria for glioma. Nat Clin Pract Oncol. 2008 Nov; 5(11):634-44.
    View in: PubMed
    Score: 0.025
  70. Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy. Expert Opin Biol Ther. 2008 Apr; 8(4):541-53.
    View in: PubMed
    Score: 0.025
  71. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol. 2003 Jun 15; 21(12):2299-304.
    View in: PubMed
    Score: 0.018
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.